2020 Controlled & Modified Drug Release Summit
By attending the unique 2020 Controlled & Modified Drug Release Summit, you will learn directly from 50+ of industry’s leading experts and hear multiple unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
This intensive 3-Day program will share innovative controlled and modified drug release strategies that will benefit your current and future product pipelines. Engage in dynamic conversation with your industry peers at our multiple networking sessions, and takeaway novel controlled and modified release strategies, which could speed up time to market and save your organization millions. *Extra value: Attend this August and gain complimentary access to the 2020 Peptide Drug Design & Development Summit (2 events co-located for the price of 1 registration).
You Will Learn
- Precision medicine & healthcare delivery: making precision medicine a reality via novel technology advancements
- Regulatory guidance for modified release dosage forms
- Advances in ocular delivery
- Micro and nanoparticle delivery
- Parenteral routes of administration
- Topical and transdermal delivery
- Oral peptide commercialization and delivery
- Enhancing patient adherence via drug delivery
- Oral drug formulation and delivery technologies
Improve The Performance Of Your Drug Products
Meet 160+ drug development professionals & learn over 2 YEARS worth of new product development strategies, formulation approaches, delivery technologies & regulatory updates while decreasing drug product time-to-market in just 3 days!
Stay Up To Date With The Latest Updates and Event Info
Beyond 2020, the global Peptide Therapeutics market is expected to eclipse $42 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include...
Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR) product, then reformulate into a once-daily...
There are a number of pharmacological and economical benefits to developing controlled and modified release drug products. Following the 505(b)(2) pathway allows companies to make modest changes to an already approved drug and get continued market exclusivity for a...
Thank You To Our Partners
2019 Speakers Included
Tycho Heimbach, PhD
Director, PK Sciences, PBPK and Biopharmaceutics, Novartis
Rakesh Dixit, PhD
Vice President, R&D, Head Biologics Safety Assessment, AstraZeneca
Mohammad Al-Sayah, PhD
Senior Scientist, Drug Product Development, Genentech Inc.
Eric Munson, PhD
Head, Department of Industrial and Physical Pharmacy, Purdue University
Yingkai Liang, PhD
Senior Scientist, Discovery Pharmaceutical Sciences, Merck & Co.
Jae Yoo, PhD
Chief Technology Officer, Aprecia Pharmaceuticals
Scott Shandler, PhD
Founder and CEO, Longevity Biotech
Vincent Ling, PhD
Senior Director, Advanced Technologies, Drug Product Development, Takeda
Di Bei, PhD
Senior Clinical Pharmacologist, Bristol-Myers Squibb
Victor Hruby, PhD
Regents Professor, Department of Chemistry, University of Arizona
Umar Maharoof, PhD
Associate Director, Dosage Form Development, Medimmune
Xiaoling Li, PhD
Associate Dean and Professor, University of the Pacific
John Lambris, PhD
Dr. Ralph and Sallie Weaver Professor of Research Medicine, University of Pennsylvania
Biplop Mitra, PhD
Principal Research Scientist, Drug Product Development, Celgene Corporation
Daniel Skomski, PhD
Senior Scientist, Merck
Shirlynn Chen, PhD
Distinguished Research Fellow, Boehringer Ingelheim